Sobi Names Kevin Springman Vice President, Franchise Head in North America
Sobi, an international biopharmaceutical company dedicated to rare diseases, announced today that Kevin Springman has joined the company as the Vice President, Franchise Head of Synagis® (palivizumab) in North America.
Springman has over 22 years of pharmaceutical and biotech experience spanning sales, marketing, market access, strategic project management and patient services. He spent two decades at AstraZeneca, most recently serving as Franchise Head of Infectious Disease. He previously served as a Senior Director of Strategic Products, and prior to that advanced through multiple sales, marketing and other commercial positions. Kevin received his bachelor’s degree from St. Joseph’s University and completed a post-graduate program at Fork Union Military Academy.
“With the completion of Sobi’s acquisition of rights to Synagis in the U.S., Sobi in North America was pleased to welcome the Synagis sales and marketing team, including Kevin as the franchise head, to our North American team. This acquisition nearly tripled the size of our organization, establishing a critical scale to drive sustainable growth in the U.S. Additionally, Kevin’s deep understanding of Synagis specifically and of strategic sales and marketing generally will make him a valuable addition to our leadership team,” said Rami Levin, President of Sobi in North America.
“I have had the privilege of helping deliver Synagis not only to physicians and hospitals but also the patients that need it for several years, and I am grateful to now have the opportunity to help Sobi continue this important work,” said Springman.
About Sobi in North America
As the North American affiliate of international biopharmaceutical company Sobi™, our team is committed to Sobi’s vision of providing access to innovative treatments that make a significant difference in the lives of individuals with rare diseases. Our product portfolio includes multiple approved treatments, focused on immunology and genetics/metabolism. With North American headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at www.sobi-northamerica.com. For more information about Sobi, visit www.sobi.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005110/en/